Internal Medicine, Hematology & Oncology · Baltimore, MD
NPI
1063495232
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
711 W 40th St Ste 427
Baltimore, MD, 21211
Phone (410) 246-4450
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.0M
279,538 services
Medicare patients, 2024
584
Average age 71
Drug cost, 2024
$11.1M
1,096 prescriptions
Company payments, 2025
$4,441
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kavita B Kalra was code J1306 (injection, inclisiran, 1 mg), 80,662 times for 158 patients. In total Kavita B Kalra billed 279,538 services in 68 codes, and Medicare paid $4.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 80,662 | 158 | $9.47 | $764K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 45,787 | 38 | $8.45 | $387K |
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 15,016 | 14 | $17.43 | $262K |
| J2182 Injection, mepolizumab, 1 mg | Office | 9,518 | 12 | $23.79 | $226K |
| J2350 Injection, ocrelizumab, 1 mg | Office | 8,433 | 29 | $43.70 | $369K |
| J0897 Injection, denosumab, 1 mg | Office | 4,681 | 46 | $20.21 | $95K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 3,328 | 13 | $6.42 | $21K |
| 96372 Injection Administration | Office | 1,339 | 286 | $11.63 | $16K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,148 | 36 | $0.23 | $266 |
| J9312 Injection, rituximab, 10 mg | Office | 887 | 16 | $60.35 | $54K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 882 | 25 | $0.09 | $79.77 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 560 | 11 | $0.08 | $42.2 |
| 96365 Intravenous Infusion, Hydration | Office | 487 | 166 | $50.52 | $25K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 416 | 85 | $4.54 | $1,887 |
| J2916 Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | Office | 405 | 11 | $1.70 | $688 |
By year: 2022 $847K for 41,264 services; 2023 $2.4M for 160,971 services; 2024 $4.0M for 279,538 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 81 | 49 | $8.65 | $701 |
Medicare prescription drug claims, 2024
In 2024, the drug Kavita B Kalra prescribed most often to Medicare patients was Procrit (Epoetin Alfa), with 96 prescriptions and refills. In total Kavita B Kalra wrote 1,096 Medicare prescriptions that cost $11.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Procrit Epoetin Alfa | 96 | 97 | 22 | $166K |
| Nucala Mepolizumab | 65 | 65 | Under 11 | $258K |
| Evenity Romosozumab-Aqqg | 57 | 57 | 13 | $137K |
| Ocrevus Ocrelizumab | 53 | 312 | 36 | $1.9M |
| Xolair Omalizumab | 48 | 48 | Under 11 | $133K |
| Anastrozole Generic | 47 | 83 | Under 11 | $417 |
| Tepezza Teprotumumab-Trbw | 33 | 33 | Under 11 | $2.4M |
| Calquence Acalabrutinib Maleate | 33 | 33 | Under 11 | $486K |
| Entyvio Vedolizumab | 32 | 49 | Under 11 | $251K |
| Saphnelo Anifrolumab-Fnia | 32 | 32 | Under 11 | $152K |
| Xtandi Enzalutamide | 26 | 26 | Under 11 | $328K |
| Rituxan Rituximab | 26 | 81 | 13 | $312K |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 24 | 35 | Under 11 | $459K |
| Oxycodone Hcl Generic | 22 | 22 | Under 11 | $276 |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | 22 | 22 | Under 11 | $274K |
Brand drugs: 906 claims; generic drugs: 190 claims; opioid claims: 25.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kavita B Kalra $4,441 ($4,441 in general payments such as food, travel and fees) from 26 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $2,794.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 5 | $2,794 |
| Novartis Pharmaceuticals Corporation NVS | 9 | $227 |
| Amgen Inc. AMGN | 10 | $175 |
| Avyxa Pharma, LLC | 1 | $167 |
| ASD Specialty Healthcare, LLC | 1 | $162 |
| Abbvie Inc. ABBV | 6 | $132 |
| Pfizer Inc. PFE | 5 | $105 |
| GlaxoSmithKline, LLC. GSK | 3 | $75.32 |
| Lundbeck LLC | 3 | $68.85 |
| Aveo Pharmaceuticals, Inc. | 2 | $56.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.